Malignant melanoma (non-metastatic)
Identifieur interne : 007200 ( Main/Curation ); précédent : 007199; suivant : 007201Malignant melanoma (non-metastatic)
Auteurs : Philip SavageSource :
- BMJ Clinical Evidence [ 1752-8526 ] ; 2007.
Abstract
The incidence of malignant melanoma has increased over the past 25 years in the UK, but death rates have remained fairly constant. Five-year survival ranges from 20% to 95% depending on disease stage. Risks are greater in white populations and in people with higher numbers of skin naevi.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent malignant melanoma? Is there an optimal surgical margin for the primary excision of melanoma? What are the effects of elective lymph node dissection in people with malignant melanoma with clinically uninvolved lymph nodes? What are the effects of sentinel lymph node biopsy in people with malignant melanoma with clinically uninvolved lymph nodes? What are the effects of adjuvant treatment for malignant melanoma? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 30 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant vaccines; elective lymph node dissection; low-, intermediate-, and high-dose adjuvant interferon alfa; sentinel lymph node biopsy; suncreens; surveillance for early recurrence; and wide excisions.
Url:
PubMed: 19454081
PubMed Central: 2943794
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004763
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :004762
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003B30
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :003414
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :003414
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003414
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007330
Links to Exploration step
PMC:2943794Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Malignant melanoma (non-metastatic)</title>
<author><name sortKey="Savage, Philip" sort="Savage, Philip" uniqKey="Savage P" first="Philip" last="Savage">Philip Savage</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19454081</idno>
<idno type="pmc">2943794</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2943794</idno>
<idno type="RBID">PMC:2943794</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">004763</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004763</idno>
<idno type="wicri:Area/Pmc/Curation">004762</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004762</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003B30</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003B30</idno>
<idno type="wicri:Area/Ncbi/Merge">003414</idno>
<idno type="wicri:Area/Ncbi/Curation">003414</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003414</idno>
<idno type="wicri:Area/Main/Merge">007330</idno>
<idno type="wicri:Area/Main/Curation">007200</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Malignant melanoma (non-metastatic)</title>
<author><name sortKey="Savage, Philip" sort="Savage, Philip" uniqKey="Savage P" first="Philip" last="Savage">Philip Savage</name>
</author>
</analytic>
<series><title level="j">BMJ Clinical Evidence</title>
<idno type="eISSN">1752-8526</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Introduction</title>
<p>The incidence of malignant melanoma has increased over the past 25 years in the UK, but death rates have remained fairly constant. Five-year survival ranges from 20% to 95% depending on disease stage. Risks are greater in white populations and in people with higher numbers of skin naevi. </p>
</sec>
<sec><title>Methods and outcomes</title>
<p>We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent malignant melanoma? Is there an optimal surgical margin for the primary excision of melanoma? What are the effects of elective lymph node dissection in people with malignant melanoma with clinically uninvolved lymph nodes? What are the effects of sentinel lymph node biopsy in people with malignant melanoma with clinically uninvolved lymph nodes? What are the effects of adjuvant treatment for malignant melanoma? We searched: Medline, Embase, The Cochrane Library and other important databases up to October 2006 (BMJ Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). </p>
</sec>
<sec><title>Results</title>
<p>We found 30 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.</p>
</sec>
<sec><title>Conclusions</title>
<p>In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant vaccines; elective lymph node dissection; low-, intermediate-, and high-dose adjuvant interferon alfa; sentinel lymph node biopsy; suncreens; surveillance for early recurrence; and wide excisions.</p>
</sec>
</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007200 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 007200 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Curation |type= RBID |clé= PMC:2943794 |texte= Malignant melanoma (non-metastatic) }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:19454081" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
This area was generated with Dilib version V0.6.31. |